Key facts
- Ottimo Pharma’s last known valuation is $242.4M (Dec 2024).
- It has raised $149.7M; the latest was Later Stage VC ($143.0M) in Dec 2024.
- Notable investors include Index Ventures, OrbiMed, The Invus Group, Samsara BioCapital, RTW Investments — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Ottimo Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Ottimo Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ottimo Pharma
Developer of cancer therapeutics designed to treat solid tumors. The company offers a bi-functional antibody that targets both immune checkpoint inhibition and angiogenesis which are pathways involved in cancer growth, enabling healthcare professionals with a dual-pathway approach that has the potential to provide effective treatment for cancer patients by attacking the disease from multiple angles.
- Sector
- Healthcare
- HQ
- Sandwich, United Kingdom
- Founded
- 2017
- Employees
- 10
- Website
- ottimopharma.com/
- Ownership
- Privately Held (backing)
Ottimo Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ottimo Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ottimo Pharma in its N-PORT filings yet. We sweep new filings monthly.